Drug Launch Success In A Changing Commercial Landscape With ACMA's William Soliman, Ph.D.
About this episode
William Soliman discusses the challenges of biotech drug launches and the importance of integrated commercialization plans.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), and Founder and CIO of White Manna Capital Partners, talks about why biotech drug launches so often miss expectations, and how to build an integrated commercialization plan that holds up with physicians, patients, and payers. William also describes the evolution in medical affairs, why standards and...
More episodes of Business Of Biotech
- Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.
- BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin
- BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.
- Targeting Tau in Alzheimer's Disease With Voyager Therapeutics' Al Sandrock, M.D., Ph.D.
- Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.